Glargine and detemir: Safety and efficacy profiles of the long-acting basal insulin analogs

References

• WildSRoglicGGreenASicreeRKingHGlobal prevalence of diabetes: Estimates for the year 2000 and 2030Diabetes Care2004271047105315111519
   PubMed Web of Science ®Google Scholar
• World Health Organization WHO Global Strategy on Diet, Physical Activity, and Health: Diabetes. Available from: http://www.who.int/dietphysicalactivity/publications/facts/diabetes/en/. Accessed 2010 Feb 28.
   Google Scholar
• The Diabetes Control and Complications Trial Research GroupThe effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitusN Engl J Med19933299779868366922
   PubMed Web of Science ®Google Scholar
• Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group: Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetesN Engl J Med20053532643265316371630
   PubMed Web of Science ®Google Scholar
• OhkuboYKishikawaHArakiEIntensive insulin therapy prevents the progression of diabetes microvascular complications in Japanese patients with NIDDM: A randomized prospective 6-year studyDiabetes Res Clin Pract1995281031177587918
   PubMed Web of Science ®Google Scholar
• UK Prospective Diabetes Study (UKPDS) GroupIntensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)Lancet19983528378539742976
   PubMed Web of Science ®Google Scholar
• HolmanRRPaulSKBethelMA10-year follow-up of intensive glucose control in type 2 diabetesN Engl J Med20083591577158918784090
   PubMed Web of Science ®Google Scholar
• American Diabetes AssociationStandards of medical care in diabetes- 2010 (Position Statement)Diabetes Care201033Suppl 1S11S6120042772
   PubMed Web of Science ®Google Scholar
• NathanDMBuseJBDavidsonMBManagement of hyperglycemia in type 2 diabetes: A consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of DiabetesDiabetes Care20093219320318945920
   PubMed Web of Science ®Google Scholar
• RodbardHWJellingerPSDavidsonJAStatement by an American Association of Clinical Endocrinologists/American College of Endocrinology consensus panel on type 2 diabetes mellitus: An algorithm for glycemic controlEndocr Pract20091554055919858063
   PubMed Web of Science ®Google Scholar
• LeporeMPampanelliSFanelliCPharmacokinetics and pharmacodynamics of subcutaneous injection of long-acting human insulin analogue glargine, NPH insulin, and ultralente human insulin and continuous subcutaneous infusion of insulin lisproDiabetes2000492142214811118018
   PubMed Web of Science ®Google Scholar
• HeiseTNosekLRonnBBLower within-subject variability of insulin detemir in comparison to NPH insulin and insulin glargine in people with type 1 diabetesDiabetes2004531614162015161770
   PubMed Web of Science ®Google Scholar
• sanofi-aventis. Lantus [package insert] Paris, France: sanofi-aventis; 2007
   Google Scholar
• Norvo Nordisk Inc Detemir [package insert]Princeton, NJNovo Nordisk2005
   Google Scholar
• KurtzhalsPHow to achieve a predictable basal insulinDiabetes Metab2005314S254S3316389895
   PubMed Web of Science ®Google Scholar
• HeinnemannLLinkeschovaRRaveKTime-action profile of the long-acting insulin analogue insulin glargine (HOE901) in comparison with those of NPH insulin and placeboDiabetes Care20002364464910834424
   PubMed Web of Science ®Google Scholar
• OwensDRCoatesPALuzioSDPharmacokinetics of 125I-labeled insulin glargine (HOE 901) in healthy menDiabetes Care20002381381910841002
   PubMed Web of Science ®Google Scholar
• KurtzhalsPEngineering predictability and protraction in a basal insulin analogue: The pharmacology of insulin detemirInt J Obes200428S23S28
   Web of Science ®Google Scholar
• HavelundSPlumARibelUThe mechanism of protraction of insulin detemir, a long-acting acylated analog of human insulinPharm Res2004211498150415359587
   PubMed Web of Science ®Google Scholar
• DeaMKHamilton-WesslerMAderMAlbumin binding of acylated insulin (NN304) does not deter action to stimulate glucose uptakeDiabetes20025176276911872677
   PubMed Web of Science ®Google Scholar
• HeiseTPieberTRTowards peakless, reproducible and long-acting insulins. An assessment of the basal analogues based on isoglycaemic clamps studiesDiabetes Obes Metab2007964865917645556
   PubMed Web of Science ®Google Scholar
• HOE 901/1015 Study Investigators Group Comparison of the time-action profiles of HOE 901 and human NPH insulin in type 1 diabetic patients using the euglycemic clamp technique. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/21981_Lantus_biopharmr.pdf. Accessed 2010 Sep 08.
   Google Scholar
• PorcellatiFRossettiPBusciantellaNRComparison of pharmacokinetics and dynamics of long-acting insulin analogs glargine and detemir at steady state in type 1 diabetes: A double-blind, randomized, crossover studyDiabetes Care2007302447245217623819
   PubMed Web of Science ®Google Scholar
• PlankJBodenlenzMSinnerFA double-blind, randomized, dose-response study investigating the pharmacodynamic and pharmacokinetic properties of the long-acting insulin analog detemirDiabetes Care2005281107111215855574
   PubMed Web of Science ®Google Scholar
• KleinOLyngeJEndahlLDamoltBNosekLHeiseTAlbumin-bound basal insulin analogues (insulin detemir and NN344): Comparable time-action profiles but less variability than insulin glargine in type 2 diabetesDiabetes Obes Metab2007929029917391154
   PubMed Web of Science ®Google Scholar
• HorvathKJeitlerKBergholdALong-acting insulin analogues versus NPH (human isophane insulin) for type 2 diabetes mellitusCochrane Database Syst Rev20072CD00561317443605
   PubMed Web of Science ®Google Scholar
• PieberTRTreichelHCHompeschBComparison of insulin detemir and insulin glargine in subjects with type 1 diabetes using intensive insulin therapyDiabet Med20072463564217381500
   PubMed Web of Science ®Google Scholar
• RosenstockJDaviesMHomePDLarsenJKoenenCSchernthanerGA randomized, 52-week, treat-to-target trial comparing insulin detemir with insulin glargine when administered as add-on to glucose-lowering drugs in insulin-naïve people with type 2 diabetesDiabetologia20085140841618204830
   PubMed Web of Science ®Google Scholar
• HollanderPCooperJBregnhojJPedersonCBA 52-week, multinational, open-label, parallel-group, noninferiority, treat-to-target trial comparing insulin detemir with insulin glargine in a basal-bolus regimen with mealtime insulin aspart in patients with type 2 diabetesClin Ther2008301976198719108786
   PubMed Web of Science ®Google Scholar
• KingABNo higher dose requirements with insulin detemir than glargine in type 2 diabetes: A cross-over, double-blind, and randomized study using continuous glucose monitoringJ Diabetes Sci Technol2010415115420167179
   PubMedGoogle Scholar
• DornhorstALuddekeHJSreenanSSafety and efficacy of insulin detemir in clinical practice: 14 week follow-up data from type 1 and type 2 diabetes patients in the PREDICTIVE European cohortInt J Clin Pract20076152352817313628
   PubMed Web of Science ®Google Scholar
• DornhorstALuddekeHJKoenenCTransferring to insulin detemir from NPH insulin or insulin glargine in type 2 diabetes patients on basal-only therapy with oral anitdiabetic drugs improves glycaemic control and reduces weight gain and risk of hypoglycemia: 14-week follow-up data from PREDICTIVEDiabetes Obes Metab200810758118034846
   PubMed Web of Science ®Google Scholar
• MeneghiniLFRosenbergKHKoenenCMerilainenMJLuddekeHJInsulin detemir improves glycaemic control with less hypoglycemia and no weight gain in patients with type 2 diabetes who were insulin naïve or treated with NPH or insulin glargine: Clinical practice experience from a German subgroup of the PREDICTIVE studyDiabetes Obes Metab2007941842717391170
   PubMed Web of Science ®Google Scholar
• YenigunMHonkaMSwitching patients from insulin glargine-based basal-bolus regimens to a once daily insulin detemir-based basal-bolus regimen: Results from a subgroup of the PREDICTIVE studyInt J Clin Pract20096342543219222627
   PubMed Web of Science ®Google Scholar
• CryerPHypoglycemia in Diabetes: Pathophysiology, Prevalence, and PreventionAlexandria, VAAmerican Diabetes Association2009
   Google Scholar
• RiddleMCRosenstockJGerichJThe treat-to-target trial: Randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patientsDiabetes Care2003263080308614578243
   PubMed Web of Science ®Google Scholar
• KurtzhalsPSchafferLSorensenACorrelations of receptor binding and metabolic and mitogenic potencies of insulin analogs designed for clinical useDiabetes200049999100510866053
   PubMed Web of Science ®Google Scholar
• HemkinsLGGrouvenUBenderRRisk of malignancies in patients with diabetes treated with human insulin or insulin analogues: A cohort studyDiabetologia2009521732174419565214
   PubMed Web of Science ®Google Scholar
• EhningerGSchmidtAHPutting insulin glargine and malignancies into perspectiveOncologist2009141169117420007644
   PubMed Web of Science ®Google Scholar
• GiovannucciEHarlanDMArcherMCDiabetes and Cancer: A consensus reportDiabetes Care2010331674168520587728
   PubMed Web of Science ®Google Scholar
• PollexEKFeigDSLubetskyAYipPMKorenGInsulin glargine safety in pregnancy: A transplacental transfer studyDiabetes Care201033293319808914
   PubMed Web of Science ®Google Scholar
• DanneTLupkeKWalteKInsulin detemir is characterized by a consistent pharmacokinetic profile across age-groups in children, adolescents, and adults with type 1 diabetesDiabetes Care2003263087309214578244
   PubMed Web of Science ®Google Scholar
• HompeschMTroupinBHeiseTTime-action profile of insulin detemir and NPH insulin in patients with type 2 diabetes from different ethnic groupsDiabetes Obes Metab2006856857316918592
   PubMed Web of Science ®Google Scholar
• HollanderPAnti-diabetes and anti-obesity medications: Effects on weight in people with diabetesDiabetes Spectr200720159165
   Google Scholar
• HermansenKDaviesMDoes insulin detemir have a role in reducing risk of insulin-associated weight gain?Diabetes Obes Metab2007920921717391147
   PubMed Web of Science ®Google Scholar
• HennigeAMSartoriusTTschritterOTissue selectivity of insulin detemir action in vivoDiabetologia2006491274128216570163
   PubMed Web of Science ®Google Scholar